Skip to content
The Intraday Markets
Pulse

Briefings

Morning BriefOvernight tape and the setup for the openMid-Morning UpdateWhat changed after the opening bell

Markets

Market DashboardTape, movers, watchlist, and cross-asset contextPre-Market SheetOvernight setup, futures, and early moversGlobal SessionsInternational clocks and index performanceInsider ActivityLatest reported executive transactions

PACB Research

Price ChartTechnical charting and drawing workspaceFundamentals ChartCompare financial metrics across timeCompany OverviewA visual snapshot of company performanceFinancial StatementsPrice, filings, key statistics, and news

Newsletter

Morning Production ReportRanked stories, charts, and newsletter readiness

Financial Statements

Explore

Markets, briefings, and company research

PACB
Pulse

Briefings

MorningMid-Morning

Markets

DashboardPre-MarketGlobalInsiders

PACB Research

ChartFundamentalsOverviewFinancials

Newsletter

Morning Report

Newsletter operations and account tools are available from your profile menu after sign-in.

PACB

$1.16
+$0.01 (0.43%)+0.43%
Open
Loading chart...
IndexN/A
Market Cap0.36B
Enterprise Value1.26B
Income$-0.43B
Sales$0.04B
EmployeesN/A
P/E-2.83
P/S3.51
P/B104.87
P/C-4.92
EV/EBITDA-36.75
EV/SalesN/A
EPS (ttm)-0.41
EarningsN/A
Gross Margin31.67%
Oper. Margin-348.46%
Profit Margin-341.47%
Volume2.99M
Shs Outstand0.31B
Change0.87%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
Income Statement by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Revenue$154.01M$200.52M$128.30M$130.51M$78.89M$90.89M$78.63M$93.47M
Cost of Revenue$116.73M$147.74M$79.27M$71.65M$46.33M$56.31M$53.53M$58.81M
Gross Profit$37.28M$52.78M$49.03M$58.86M$32.57M$34.58M$25.10M$34.66M
Gross Margin24.21%26.32%38.22%45.10%41.28%38.04%31.92%37.08%
Operating Expenses$511.60M$387.25M$356.23M$269.30M$136.95M$135.12M$126.08M$124.44M
Operating Income$-474.31M$-334.47M$-307.20M$-210.44M$-104.39M$-100.55M$-100.99M$-89.78M
Operating Margin-307.97%-166.80%-239.43%-161.24%-132.31%-110.62%-128.44%-96.06%
Net Income$-309.85M$-306.74M$-314.25M$-181.22M$29.40M$-84.13M$-102.56M$-92.19M
Net Margin-201.18%-152.97%-244.92%-138.85%37.27%-92.57%-130.44%-98.63%
EPS (Basic)$-1.13$-1.21$-1.40$-0.89$0.18$-0.51$-0.76$-0.87
EBITDAN/AN/AN/AN/AN/AN/AN/AN/A
Stock Option Compensation ExpenseN/AN/AN/AN/AN/AN/AN/AN/A
Price To Earnings RatioN/AN/AN/AN/AN/AN/AN/AN/A
Price To Sales RatioN/AN/AN/AN/AN/AN/AN/AN/A
Shares OutstandingN/AN/AN/AN/AN/AN/AN/AN/A
Market CapitalizationN/AN/AN/AN/AN/AN/AN/AN/A
Balance Sheet by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Cash & Short Term InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Short Term ReceivablesN/AN/AN/AN/AN/AN/AN/AN/A
InventoriesN/AN/AN/AN/AN/AN/AN/AN/A
Other Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Net Property, Plant & EquipmentN/AN/AN/AN/AN/AN/AN/AN/A
Total Investments and AdvancesN/AN/AN/AN/AN/AN/AN/AN/A
Long-Term Note ReceivableN/AN/AN/AN/AN/AN/AN/AN/A
Intangible AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Other AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Assets$1.26B$1.75B$1.77B$2.01B$413.98M$147.99M$170.28M$144.08M
Short Term Debt Incl. Current Port. of LT DebtN/AN/AN/AN/AN/AN/AN/AN/A
Accounts PayableN/AN/AN/AN/AN/AN/AN/AN/A
Income Tax PayableN/AN/AN/AN/AN/AN/AN/AN/A
Other Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Provision for Risks ChargesN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Other LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Liabilities$753.85M$1.04B$1.20B$1.22B$78.49M$93.07M$56.21M$57.98M
Non-Equity ReservesN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Stock - Carrying ValueN/AN/AN/AN/AN/AN/AN/AN/A
Common EquityN/AN/AN/AN/AN/AN/AN/AN/A
Total Shareholders Equity$506.59M$701.30M$562.90M$790.99M$335.49M$54.92M$114.06M$86.10M
Accumulated Minority InterestN/AN/AN/AN/AN/AN/AN/AN/A
Total Equity$506.59M$701.30M$562.90M$790.99M$335.49M$54.92M$114.06M$86.10M
Total Liabilities & Stockholders Equity$1.26B$1.75B$1.77B$2.01B$413.98M$147.99M$170.28M$144.08M
Book Value Per ShareN/AN/AN/AN/AN/AN/AN/AN/A
Tangible Book Value Per ShareN/AN/AN/AN/AN/AN/AN/AN/A
Full-Time EmployeesN/AN/AN/AN/AN/AN/AN/AN/A
Price to Book RatioN/AN/AN/AN/AN/AN/AN/AN/A
Return on AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Return on EquityN/AN/AN/AN/AN/AN/AN/AN/A
Return on Invested CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Quick RatioN/AN/AN/AN/AN/AN/AN/AN/A
Current RatioN/AN/AN/AN/AN/AN/AN/AN/A
Cash Flow by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Net Income$-309.85M$-306.74M$-314.25M$-181.22M$29.40M$-84.13M$-102.56M$-92.19M
DepreciationN/AN/AN/AN/AN/AN/AN/AN/A
Other Funds (Non Cash)N/AN/AN/AN/AN/AN/AN/AN/A
Funds from OperationsN/AN/AN/AN/AN/AN/AN/AN/A
Extraordinary ItemN/AN/AN/AN/AN/AN/AN/AN/A
Changes in Working CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Income Taxes PayableN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Operating Activities$-206.06M$-266.55M$-263.21M$-111.18M$19.50M$-78.31M$-66.43M$-67.52M
Capital ExpendituresN/AN/AN/AN/AN/AN/AN/AN/A
Net Assets From AcquisitionsN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Fixed Assets and BusinessesN/AN/AN/AN/AN/AN/AN/AN/A
Purchase or Sale of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Purchase of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Sale Or Maturity of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Other UsesN/AN/AN/AN/AN/AN/AN/AN/A
Other SourcesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Investing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Cash Dividends PaidN/AN/AN/AN/AN/AN/AN/AN/A
Change in Capital StockN/AN/AN/AN/AN/AN/AN/AN/A
Repurchase of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Proceeds from Stock OptionsN/AN/AN/AN/AN/AN/AN/AN/A
Issuance or Reduction of Debt, NetN/AN/AN/AN/AN/AN/AN/AN/A
Change in Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Issuance of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Reduction of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Net Financing Active Other Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Other Financing Activities UsesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Financing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Exchange Rate EffectN/AN/AN/AN/AN/AN/AN/AN/A
Net Change in CashN/AN/AN/AN/AN/AN/AN/AN/A
Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Dividends (Cash Flow)N/AN/AN/AN/AN/AN/AN/AN/A
Price to Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A

Company coverage

Latest news

20 stories
Aug 6 · 2:52PMAI Disruption Reshapes Bioinformatics: Record Investment and Breakthrough Tools Signal a New Era for Drug Discovery and Precision MedicineGlobeNewswire Inc. ↗Apr 29 · 5:00PMGlobal Metagenomics Sequencing Market to Register Stunning Growth at a CAGR of ~13% by 2034 | DelveInsightGlobeNewswire Inc. ↗Apr 24 · 8:59AMOmics-Based Clinical Trials Research Report 2026: $47.78 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FGlobeNewswire Inc. ↗Apr 7 · 5:44PMGlobal DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical ApplicationsGlobeNewswire Inc. ↗Oct 31 · 7:15AMGenomics Data Analysis Market Size to Surpass USD 28.74 Bn by 2034GlobeNewswire Inc. ↗Aug 6 · 1:00PMPacBio to Present at Upcoming Investor ConferencesGlobeNewswire Inc. ↗Jun 21 · 12:00PMLong Read Sequencing Market Projected to Reach USD 6.98 Billion by 2032, Driven by Advances in Genomics and Precision Medicine – SNS InsiderGlobeNewswire Inc. ↗May 14 · 8:30AMMetagenomics Market Size, Share, Forecast & Trends Analysis Report 2025: Market to Soar to $6.71 Billion by 2031, Driven by Agri Genomics and Genome MappingGlobeNewswire Inc. ↗
Show 12 more stories↓
May 12 · 2:56PMPacBio Board Independent Investigation Concludes Allegations UnsubstantiatedGlobeNewswire Inc. ↗Feb 15 · 4:09AMPacBio Grants Equity Incentive Award to New EmployeeGlobeNewswire Inc. ↗Jan 20 · 12:00PMRNA Transcriptome Profiling Tests Market Expands at 14.5% CAGR, Surpassing US$ 37 Billion by 2034 | Fact.MR ReportGlobeNewswire Inc. ↗Jan 15 · 12:00PMNeurogenomics Market Forecast and Trends Analysis to 2031: Healthcare Investments and Early Detection Drive Robust Uptake of Neurogenomics SolutionsGlobeNewswire Inc. ↗Jan 7 · 4:55PMCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtThe Motley Fool ↗Nov 28 · 1:00PMShrimp Hydrolysate Market Set to Surge to $675.9 Million with an Impressive 8.7% CAGR by 2034GlobeNewswire Inc. ↗Nov 12 · 4:55PMCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtThe Motley Fool ↗Nov 7 · 3:35AMPacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the BenchtopGlobeNewswire Inc. ↗Aug 15 · 2:58PMLaboratory-Developed Tests (LDTs) World Market Forecast Report to 2028, with Coverage of the Effects of the FDA's New "Medical Devices: Laboratory Developed Tests" Rule, Passed in April 2024GlobeNewswire Inc. ↗Aug 7 · 1:01PMAntibody Production Market to Surpass USD 36.49 Billion by 2032 Driven by Escalating Demand for Targeted Therapies and Technological Advancements | Research by SNS InsiderGlobeNewswire Inc. ↗Aug 7 · 6:43AM3 Conviction Bets Cathie Wood Is Doubling Down OnInvesting.com ↗Jul 2 · 3:56PMReasons to Retain PacBio (PACB) Stock in Your Portfolio NowZacks Investment Research ↗

Insider Trading

View All
Insider
Type
Shares
Price
Value
Date
Van Oene Mark
Award
489.1K
—
—
Aug 10, 26
ORDONEZ KATHY
Award
223.5K
$1.58
$353K
Jun 3, 26
MILLIGAN JOHN F
Award
223.5K
$1.58
$353K
Jun 3, 26
Ericson William W.
Award
223.5K
$1.58
$353K
Jun 3, 26
LIVINGSTON RANDALL S
Award
223.5K
$1.58
$353K
Jun 3, 26

Company

CEO: Mark Van OeneEmployees: 485www.pacb.com
About the company↓

Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.

Discover more

You may be interested in
AMD

Advanced Micro Devices

$507.91

↑ 5.24%
ABX

Abacus Global Management Inc

$9.25

↑ 8.57%
TSLA

Tesla Inc

$341.35

↑ 0.45%
GOOGL

Alphabet Inc

$345.62

↓ 0.25%
NVDA

NVIDIA Corp

$224.96

↓ 0.15%
META

Meta Platforms Inc

$591.01

↓ 0.70%
BAC

Bank of America Corp

$64.47

↑ 0.57%
MA

Mastercard Inc

$569.70

↑ 0.47%
INTC

Intel Corp

$102.92

↓ 1.59%
V

Visa Inc

$365.50

↓ 0.00%
AMZN

Amazon.com Inc

$262.91

↓ 0.84%
IBM

IBM Corp

$234.88

↓ 0.92%
The Intraday Markets

© 2026 The Intraday. All rights reserved.

Market data may be delayedFor informational purposes onlyFMP · Massive · SEC